Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Ipsen
Ipsen
Nektar Therapeutics
Ludwig Institute for Cancer Research
Eli Lilly and Company
Daiichi Sankyo
INSYS Therapeutics Inc